De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Xencor Beheer

Beheer criteriumcontroles 2/4

De CEO Xencor's is Bassil Dahiyat, benoemd in Aug1997, heeft een ambtstermijn van 27.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.97M, bestaande uit 8.8% salaris en 91.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.35% van de aandelen van het bedrijf, ter waarde $ 4.94M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 7.5 jaar.

Belangrijke informatie

Bassil Dahiyat

Algemeen directeur

US$8.0m

Totale compensatie

Percentage CEO-salaris	8.8%
Dienstverband CEO	27.2yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	7.5yrs

Recente managementupdates

Recent updates

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Feb 27

Xencor: Standing Out With XmAb Technology

Feb 03

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Jan 05

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Nov 13

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Nov 10

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Aug 08

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Aug 12

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Aug 03

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Jun 03

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Feb 18

Upgrade: Analysts Just Made A Huge Increase To Their Xencor, Inc. (NASDAQ:XNCR) Forecasts

Aug 06

Analyse CEO-vergoeding

Hoe is Bassil Dahiyat's beloning veranderd ten opzichte van Xencor's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$133m
Dec 31 2023	US$8m	US$700k	-US$126m
Sep 30 2023	n/a	n/a	-US$119m
Jun 30 2023	n/a	n/a	-US$128m
Mar 31 2023	n/a	n/a	-US$140m
Dec 31 2022	US$8m	US$670k	-US$55m
Sep 30 2022	n/a	n/a	US$30m
Jun 30 2022	n/a	n/a	US$22m
Mar 31 2022	n/a	n/a	US$109m
Dec 31 2021	US$5m	US$625k	US$83m
Sep 30 2021	n/a	n/a	-US$4m
Jun 30 2021	n/a	n/a	US$24m
Mar 31 2021	n/a	n/a	-US$64m
Dec 31 2020	US$4m	US$600k	-US$69m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$80m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$4m	US$567k	US$27m
Sep 30 2019	n/a	n/a	US$36m
Jun 30 2019	n/a	n/a	US$49m
Mar 31 2019	n/a	n/a	US$39m
Dec 31 2018	US$4m	US$550k	-US$70m
Sep 30 2018	n/a	n/a	-US$45m
Jun 30 2018	n/a	n/a	-US$71m
Mar 31 2018	n/a	n/a	-US$53m
Dec 31 2017	US$5m	US$525k	-US$38m

Compensatie versus markt: De totale vergoeding ($USD 7.97M ) Bassil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Bassil is gestegen terwijl het bedrijf verliesgevend is.

CEO

Bassil Dahiyat (54 yo)

27.2yrs

Tenure

US$7,965,955

Compensatie

Dr. Bassil I. Dahiyat, Ph D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat serves as an Independent Director at Terray Ther...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bassil Dahiyat	Co-Founder	27.2yrs	US$7.97m	0.35% $ 4.9m
John Desjarlais	Executive VP of Research & Chief Scientific Officer	10.3yrs	US$3.21m	0.22% $ 3.1m
Celia Eckert	Senior VP	5.1yrs	US$2.02m	0.027% $ 372.0k
Nancy Valente	Executive VP & Chief Development Officer	1.4yrs	US$5.35m	0.013% $ 184.3k
Bart Cornelissen	Senior VP & CFO	less than a year	geen gegevens	geen gegevens
Charles Liles	Associate Director and Head of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Jennifer Sandoz	Senior VIce President of Human Resources	3.2yrs	geen gegevens	geen gegevens
Jeremy Grunstein	Senior Vice President of Business Development	2.8yrs	geen gegevens	geen gegevens
Kirk Rosemark	Senior Vice President of Regulatory Affairs & Quality Assurance	2.8yrs	geen gegevens	geen gegevens
Eric Kowack	Senior Vice President of Program Leadership & Alliance Management	1.8yrs	geen gegevens	geen gegevens
Dane Leone	Senior VP of Corporate Strategy	less than a year	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van XNCR wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bassil Dahiyat	Co-Founder	27.2yrs	US$7.97m	0.35% $ 4.9m
Richard Ranieri	Independent Director	6.8yrs	US$347.02k	0.0036% $ 49.7k
Alan Montgomery	lead Independent Director	9.6yrs	US$384.19k	0.013% $ 181.4k
Kevin Gorman	Independent Director	7.5yrs	US$342.50k	0.0034% $ 47.7k
Jeffrey Ravetch	Member of Scientific Advisory Board	15.3yrs	geen gegevens	geen gegevens
Ellen Feigal	Independent Director	5.9yrs	US$348.00k	0.012% $ 168.5k
Kurt Gustafson	Independent Director	10.3yrs	US$346.50k	0.0050% $ 69.5k
Dagmar Rosa-Bjorkeson	Independent Director	4.8yrs	US$346.25k	0.012% $ 168.5k
Barbara Klencke	Independent Director	1.1yrs	US$467.35k	geen gegevens

7.5yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van XNCR wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.5 jaar).

Xencor Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Xencor Appoints Bart Cornelissen as Senior Vice President

Co-Founder recently sold US$294k worth of stock

Co-Founder notifies of intention to sell stock

Insider notifies of intention to sell stock

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Recent updates

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Xencor, Inc. has filed a Follow-on Equity Offering.

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)

Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?

Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Consensus revenue estimates fall by 18%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Co-Founder recently sold US$294k worth of stock

Co-Founder notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Xencor: Standing Out With XmAb Technology

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Co-Founder notifies of intention to sell stock

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Price target decreased by 7.0% to US$40.50

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Consensus revenue estimates increase by 19%

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Co-Founder notifies of intention to sell stock

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Consensus EPS estimates fall by 20%

Insufficient new directors

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder recently sold US$183k worth of stock

Consensus revenue estimates decrease by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improves as stock rises 15%

Senior VP & Chief Medical Officer recently sold US$101k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

Price target decreased to US$50.13

Consensus revenue estimates increase by 40%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations